Stocks · News reference
Armata Pharmaceuticals Announces Promotion Of David House To CFO
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Armata Pharmaceuticals Q2 EPS $(0.27) Beats $(0.45) Estimate, Sales $2.510M Beat $420.000K Estimate
Armata Pharmaceuticals (AMEX:ARMP) reported quarterly losses of $(0.27) per share which beat the analyst consensus estimate of $(0.45) by 38.64 percent. This is a 40 percent increase over losses of $(0.45) per share
Why Is Armata Pharma Stock Gaining Monday?
ARMP stock jumps 10% as Armata Pharmaceuticals prepares its AP-SA02 multi-phage candidate for a pivotal Phase 3 trial in late 2026.